glp 1 research GLP-1 weight loss drugs leave users low on key nutrients, study finds GLP-1 Agonists Market Report 2025-2033,

The New England Journal of Medicine, 391 (2), 109121

At least two clinical trials are currently ongoing for OUD, investigating both liraglutide (Freet et al., 2024) and semaglutide (Freet et al., 2025)

Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes

patients baseline score = 27), a validated 10-item instrument used to assess several alcohol addiction-specific metrics, including consumption frequency, binge patterns, and alcohol-related consequences

Subgroup analyses suggest that older adults and those with more metabolic resistance tend toward the lower end of that range, but 10 to 15 percent body weight reduction over 12 to 18 months is a realistic expectation for many patients over 50

Drug interactions you should be aware of on GLP-1 medications 1